Locations
Waltham, MA, USA
industry
Biotechnology · DeepTech · Health
Size
51-200 employees
Stage
Other
founded in
2009
KALA BIO is a clinical-stage biopharmaceutical company focused on developing innovative therapies for rare and serious eye diseases using its proprietary mesenchymal stem cell secretome (MSC-S) platform. The company is advancing its pipeline with therapies like KPI-012, currently in Phase 2b clinical study for persistent corneal epithelial defect, and KPI-014, a preclinical intravitreal therapy for inherited retinal diseases. KALA BIO has previously secured FDA approval for two ophthalmic products, EYSUVIS® and INVELTYS®, and has shifted its focus to biologics after selling its commercial products to Alcon Inc. The company aims to improve vision and change lives through its commitment to research and development in the ophthalmic space.
Something looks off?